Measles Outbreak Cases Cross 100 Mark In US, Australia Sees Sudden Surge Of The Infectious Disease

Updated Feb 23, 2025 | 11:46 AM IST

SummaryMeasles continues to create havoc with over 100 people infected in US. New health guidelines and advisories are being issued to ensure people remain safe and vigilant.
(Credit-Canva)

(Credit-Canva)

The current measles outbreak has gripped US states like Texas and New Mexico leaving people worried whether it would become a new pandemic. According to the Texas Department of State Health Services as of February 21, 90 cases were diagnosed in the last month in the South Plains area, with at least 77 of them were reported in children and teens under 17.

Measles is highly contagious and can be deadly. The outbreak, which started spreading in late January, has resulted in multiple hospitalizations, with at least nine confirmed cases and three probable cases as of early February. Health officials caution that at least one in five infected individuals will have to be hospitalized, highlighting the severity of the situation.

Misinformation surrounding vaccines and with the new Trump administration anti-vaccine campaigs, has causing parents to hesitate or refuse vaccination.

Furthermore, the country down under Australia is also witnessing a surge in measles cases as health officials in Sydney have issued an urgent alert, urging residents to watch for measles symptoms after an infected individual visited several places in Sydney over the last seven days.

Authorities report that the traveller had returned from South East Asia where there are ongoing outbreaks of measles.

What Are The Symptoms Measles?

Key symptoms of measles include fever, a runny nose, sore eyes, and a cough. Typically, a red, blotchy rash appears three to four days later, spreading from the head down to the body. Symptoms can manifest between 7 and 18 days after exposure.

Anyone who experiences these symptoms after potential exposure should immediately contact their doctor or emergency department. It is crucial to call ahead before visiting to avoid potentially exposing others in the waiting room. Dr. Selvey also highlighted that ongoing measles outbreaks are occurring in various parts of the world, making awareness and prompt action essential.

Why It Is Important To Get Vaccinated?

According to CDC everyone should get the MMR vaccine. It protects you from measles, mumps, and rubella. Getting vaccinated helps stop these diseases from spreading. There are two safe MMR vaccines available. They work the same way, so it doesn't matter which one you get. Kids can also get a shot that protects against chickenpox too, but this is only for children.

Who Should Get Vaccinated?

Kids Need Two Shots

All children should get two MMR shots. The first shot should be given when they are between 12 and 15 months old. The second shot should be given when they are between 4 and 6 years old. If needed, the second shot can be given earlier, but it must be at least 28 days after the first shot.

College Students Need to Be Protected

Students going to college or other schools after high school, need two shots if they are not already immune. The shots must be at least 28 days apart.

Adults Need at Least One Shot

Most adults need at least one MMR shot. Some adults need two shots, especially those who work in healthcare, travel a lot, or go to college. These people should get two shots, with 28 days between them.

Travelers Need to Be Extra Careful

Anyone traveling to other countries should make sure they are protected. Babies 6 to 11 months old should get one shot before traveling. Kids 12 months and older, teens, and adults need two shots, with 28 days between them.

Healthcare Workers Must Be Immune

People who work in healthcare should have proof that they are immune to measles, mumps, and rubella. If they are not immune, they need two MMR shots, spaced 28 days apart.

Women Thinking About Having Babies

Women who might get pregnant should talk to their doctor about the MMR vaccine. It's safe to get the shot while breastfeeding.

End of Article

WHO Says Ebola Fight Is Catching Up; Expert Explains Science Behind Patient Recoveries

Updated Jun 6, 2026 | 12:11 PM IST

SummaryA total of 381 Ebola cases have been confirmed in the Democratic Republic of Congo, including 63 deaths. Uganda has reported 16 confirmed cases. Six people in the DRC and two in Uganda have recovered to date.

Credit: Canva/WHO

After previously warning that Ebola was "outpacing us," WHO Director-General Tedros Adhanom Ghebreyesus said on Thursday that "we are catching up" as efforts to contain the outbreak in the Democratic Republic of Congo show progress.

A total of 452 Ebola cases have been confirmed in the Democratic Republic of Congo, including 82 deaths. Uganda has reported 16 confirmed cases. Meanwhile, the number of suspected cases has fallen from more than 1,000 last week to 116 as health teams work through the backlog.

WHO Sees Signs of Progress

“What I saw gave me hope,” Ghebreyesus said at a press conference.

“The outbreak had a big head start, and we're still behind, but under the leadership of the Government of DRC, we are catching up,” he added.

Importantly, he noted that six people in the DRC and two in Uganda have recovered to date, “showing that people can survive Ebola if they have access to care and go to health facilities as soon as they show symptoms.”

Why Are Patients Recovering?

The latest outbreak is caused by the Bundibugyo strain of the Ebola virus, for which there is currently neither a vaccine nor an antiviral treatment. So how are patients recovering?

Dr. Rajeev Jayadevan, Co-Chairman of the National IMA COVID Task Force and Past President of the Indian Medical Association, Cochin, told HealthandMe that a combination of factors—including the virus strain, access to medical care, and individual immune responses—can significantly influence whether a patient survives the disease.

WHO Says Ebola Fight Is Catching Up; Expert Explains Science Behind Patient Recoveries

Ebola virus disease is a severe illness caused by different strains of the Ebola virus. The current outbreak is linked to the Bundibugyo strain, which has a lower mortality rate than the more lethal Zaire strain responsible for several previous outbreaks, he said.

“The mortality of Ebola virus disease is tied to several components,” Dr. Rajeev explained.

Early Medical Care Improves Survival

One of the most important factors is access to early medical attention and supportive care. Patients who receive prompt treatment at well-equipped healthcare facilities staffed by experienced healthcare workers have a much greater chance of survival.

However, such healthcare access is often limited in outbreak-affected regions of Africa due to ongoing conflicts and socioeconomic challenges.

“The chance of survival is much higher if a person receives good medical attention and early supportive care,” he said.

Bundibugyo Strain vs Zaire Strain

Also read: Ebola Bundibugyo Strain: All You Should Know About The Rare Virus

The strain of the virus also plays a critical role. Dr. Rajeev said that because the Bundibugyo strain is less lethal than the Zaire strain, more infected individuals are expected to survive under similar conditions.

“If a hundred people get infected with the Zaire strain and another hundred with the Bundibugyo strain, more people in the Bundibugyo group will survive, all other conditions remaining the same,” he said.

Difference In Immune Response

Another important factor is the body's immune response, which varies from person to person. Dr. Rajeev highlighted the role of human leukocyte antigens (HLA), proteins that help the immune system recognize and respond to invading pathogens. Because each individual's HLA profile is unique, people infected with the same virus can generate different immune responses.

“HLA works closely with the immune system by presenting pieces of the virus to immune cells, helping the body build a targeted response,” he said.

Also read: Ebola Alert In India: Rajasthan, Hyderabad Report Suspected Cases of Deadly Virus

This biological diversity is one reason why the same infection can affect individuals differently. It is also considered an evolutionary safeguard that helps prevent a single pathogen from devastating the entire human population.

The Role of Probability

Dr. Rajeev also pointed to a simple statistical reality. “If the mortality rate in the current outbreak is around 30 per cent, that means about 70 per cent of infected individuals are expected to survive,” he said.

According to the expert, survival often results from a combination of favorable factors, including infection with a less lethal strain, timely medical care, a strong immune response, and the overall probability of recovery within a given outbreak.

End of Article

Ovarian Cancer: UK NHS Rolls Out First Major Drug In Over 20 Years

Updated Jun 5, 2026 | 06:00 PM IST

Summary​The last major NHS treatment introduced for patients with ovarian cancer was the rollout of liposomal doxorubicin and paclitaxel in the early 2000s.
Ovarian Cancer: UK NHS Rolls Out First Major Drug In Over 20 Years

Credit: Canva

The UK National Health Service (NHS) has approved the free rollout of a breakthrough ovarian cancer drug, benefiting hundreds of women with hard-to-treat cancer starting today.

Importantly, the US FDA-approved drug is the first new addition to NHS treatment for this group of patients in over 20 years.

The last major NHS treatment introduced for these patients was the rollout of liposomal doxorubicin and paclitaxel in the early 2000s.

The NHS, in a statement, said that the new targeted therapy, mirvetuximab soravtansine, will be offered to patients living with ovarian cancer whose disease has stopped responding to standard (platinum-based) chemotherapy, providing new hope of extra time to live.

Mirvetuximab soravtansine (Elahere) has been developed by AbbVie. The NHS estimates up to 400 patients in England each year could benefit.

“This represents the most significant breakthrough in NHS treatment for these hard-to-treat ovarian cancers in over two decades – and we’re delighted it will now offer hundreds of women much-needed hope of precious extra time with their loved ones,” said Professor Ruth Plummer, NHS national clinical lead for cancer drugs.

How Does The Drug Work?

According to the NHS, the drug combines a ‘homing’ antibody with a cancer-killing medicine, often described by scientists as a ‘biological missile’ or ‘Trojan horse’ therapy.

It works by attaching to ovarian cancer cells that have a protein called folate receptor alpha (FRα) on their surface, before releasing a cancer-killing molecule that destroys the cell from within.

In a major global clinical trial involving eight NHS hospitals, the treatment delayed cancer progression and prolonged survival, with patients living 16.5 months on average compared to 12.8 months with chemotherapy.

Also read: New Pancreatic Cancer Drug Daxaronrasib May Benefit Patients With Lung And Ovarian Tumors Too

Who Can Avail The Drug Through The NHS?

Following a recommendation by the National Institute for Health and Care Excellence (NICE), the treatment will be available for:

  • patients with epithelial ovarian cancer,
  • peritoneal or fallopian tube cancer that has become resistant to platinum-based chemotherapy
  • whose tumors contain the FRα protein targeted by the drug.

The treatment is given intravenously (via a drip) over two to four hours, once every three weeks.

Are There Any Side Effects?

The NHS stated that the drug may also have more tolerable side effects than traditional chemotherapy, as it is aimed more precisely at cancer cells than chemotherapy, which can also harm healthy cells.

Common side effects include:

  • Eye problems such as blurred vision or dry eyes
  • Tiredness
  • Nausea
  • Low blood counts

Most side effects are manageable with monitoring and supportive care.

Read More: Alan Brazil Shares Survival Story After Heart Stopped During Liver Transplant

Ovarian Cancer Remains A Major Health Challenge

Ovarian cancer is one of the leading causes of death from gynecological cancer worldwide. In the UK, there are around 7,500 new diagnoses each year.

Standard treatment for ovarian cancer typically involves surgery and chemotherapy, but around 80 per cent of patients with advanced disease relapse, and most eventually develop resistance to chemotherapy.

More than a third of patients (37 per cent) treated with mirvetuximab soravtansine also saw their tumors shrink by at least 30 per cent, compared to 16 per cent of patients receiving chemotherapy in clinical trials.

End of Article

FIFA World Cup 2026: Why Health Officials Are Watching More Than Just the Matches

Updated Jun 6, 2026 | 09:00 AM IST

SummaryThe FIFA World Cup 2026 is from 11 June. This is the biggest edition of the tournament so far. As the competition spreads throughout North America, there is a huge risk of diseases.
FIFA World Cup 2026: Why Health Officials Are Watching More Than Just the Matches

Credit: AI generated image

The FIFA World Cup's 2026 edition is at the doorstep. Different countries have geared up, and their fans are also very much ready to witness and enjoy one of the biggest sporting events in the world, as it comes after a long four years. Among these preparations, a particularly important role is played by the health officials of the United States.

The authorities are getting ready as the tournament is set to begin, and this time it will be played in three different nations, including the United States, Canada, and Mexico. Notably, this time, 48 teams will take part, 16 host cities in North America.

Though there are many concerns as this tournament of global influence is starting at a time when Ebola has spread in Congo and Uganda, and the World Health Organization has designated a “public health emergency of international concern.”

According to local media reports, experts and authorities are not panicking about the spread of Ebola; they are more concerned about diseases like measles, one of the world’s most contagious diseases, along with COVID-19 and influenza. There is also fear of arboviruses spread by infected insects, such as dengue.

Also Read: CDC Warns That Tick Bites Are Surging Across The US: What You Need to Know

Although Ebola does not spread as easily as COVID and other respiratory diseases, there is no carelessness regarding the risk the disease brings, so the Centers for Disease Control and Prevention has taken entry measures for travelers from countries linked to the outbreak. If a traveler has visited any nation with an outbreak within the previous 21 days, they will enter through designated airports in Atlanta, Houston, New York, or Washington.

The screening process will also go on after the airport, as health authorities will be informed, and the traveler will be under observation.

CDC said it is “actively engaged in World Cup preparedness as part of the federal coordination structure led by the White House FIFA World Cup 2026 Task Force.”

Also Read: The Mystery Behind Trump’s Hair-Loss Drug And The Bigger Health Questions It Raises

Why Ebola Does Not Spread Like COVID-19?

Ebola is a serious viral hemorrhagic disease. Ebola does NOT spread through casual airborne exposure like influenza or COVID-19. Individuals become infectious only after symptoms begin, not during the incubation period. The incubation period ranges from 2 to 21 days. It does not spread through the air like respiratory viruses. It spreads only through direct contact with infected body fluids.

Ebola is not airborne. There's no evidence of that at all. To be infected, you've got to have body fluid contact with someone who is quite ill. You cannot get Ebola from passing someone in an airport, sitting near someone freely, or through other casual contacts. The stricter infection control, timely isolation, and avoiding direct contact with infected persons remain key preventive measures.

End of Article